StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Intercept (ICPT) NASH Trial Updates Offers 'Positives and Negatives' - Baird
February 10, 2017 12:17 PM
Baird analyst Brian Skorney said today's REGENERATE amendments from Intercept Pharmaceuticals (NASDAQ: ICPT) offer 'Positives and Negatives', although he is ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Next Articles
Intercept (ICPT) NASH Trial Amendment Doesn't Change Probability of Success - Cantor Fitzgerald
February 10, 2017 12:39 PM
Intercept Pharmaceuticals (ICPT) Trial Amendments 'Increase Probability for Success' - Wedbush
February 10, 2017 12:31 PM
Intercept Pharmaceuticals (ICPT) NASH Trial Changes Increase Probability of Success and Timely Approval - BMO
February 10, 2017 11:40 AM
Intercept (ICPT) NASH Trial Changes Lowers the Hurdle for Success - FBR
February 10, 2017 11:35 AM
UPDATE: Intercept Pharma (ICPT) Changes Main Goal in Phase Three Nash Study with OCA - Bloomberg
February 10, 2017 8:37 AM
Intercept Pharma (ICPT) Falls 10% Ahead of Update on Phase 3 Trial of OCA
February 10, 2017 8:18 AM
Intercept Pharma (ICPT) to Provide Update on Phase 3 REGENERATE Trial of OCA in NASH Today
February 10, 2017 7:05 AM
Intercept to Provide Update on Phase 3 REGENERATE Trial of Obeticholic Acid for the Treatment of NASH Patients with Liver Fibrosis
February 10, 2017 7:00 AM
